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receptor antagonist co-therapy in patients at a high risk
of NSAID-associated gastrointestinal complications ap-
pears not to be justified. Despite substantial confounding
between the use of ulcer-healing drugs and recorded risk
factors; in the setting of primary care, misoprostol and, to
a lesser extent, proton-pump inhibitors appeared to be ef-
fective in reducing hospitalization for gastrointestinal
events associated with NSAID use.
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OBJECTIVE: With the increase of QoL assessment in
clinical trials, it is necessary to have cross-culturally valid
instruments to pool data across countries.
METHODS: The initial version of the PAC-SYM was de-
signed in US English to assess frequency and intensity of
constipation symptoms and patients’ evaluation of their
condition in relation to treatment. Prior to use in an in-
ternational trial, it had to undergo linguistic validation in
12 languages. This involved the recruitment of a QoL
specialist in each country. Two independent forward
translations in the target languages were reconciled and
back-translated into English. Translations were tested for
comprehension in a sample target population, compared
and internationally harmonized.
RESULTS: The developer clarified concepts underlying
each item, but translation problems involved finding con-
ceptual equivalents of typical US expressions and re-
sponse choices. For example, use of similar terms desig-
nating one concept could not systematically be retained
in all languages. Expressions such as “loose stools” and
“watery stools” had only one equivalent in most lan-
guages. In conjunction with psychometric results, this
item was deleted. The term “abdomen” presented two
translation alternatives in most languages, designating ei-
ther the top or lower part of this area. To maximize com-
prehension, the most common term was retained. Finally,
it was impossible to produce a direct equivalent of “ex-
tremely well” in the Scandinavian languages. The option
“very well” was therefore chosen.
CONCLUSION: Prior to use in an international trial, rig-
orous cultural adaptation is essential to producing cross-
culturally valid language versions of the PAC-SYM. Re-
sults from linguistic and psychometric validation facili-
tated item reduction and establishment of a final ques-
tionnaire. Further psychometric testing will be important
to ensure similar relationships among scales across coun-
tries. This work highlights the value of international in-
put in instrument design.
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Non-steroidal anti-inflammatory drugs (NSAIDs) cause
both minor and severe gastrointestinal (GI) side effects.
Significant amounts of healthcare resources are used to
prevent/manage these side effects. Arthrotec is a combi-
nation of an NSAID (diclofenac) and a gastroprotective
agent (GPA, misoprostol) that is thought to decrease
NSAID-induced side effects.
OBJECTIVE: To investigate whether there is a reduction
in GPA use, diagnostic tests, and hospitalizations attrib-
uted to Arthrotec versus other NSAIDs among an elderly
population.
METHODS: We analyzed a 10% random sample (n 
73,850 patients) of the Régie de l’assurance-maladie du
Québec (RAMQ) database collected between January
1993 and December 1997. Patients were eligible for the
study if they were free of NSAIDs, GPAs, and upper gas-
trointestinal diagnostic tests during the year preceding the
index date (the date of first NSAID dispensation during
the study period). The patients were followed for 2 years.
RESULTS: Of 9,618 patients included in the study, 1,153
were started on Arthrotec and 8,465 on any other NSAID.
Comorbidity markers were not significantly different in
the two groups. Of the Arthrotec patients 17 (1.5%) were
hospitalized for GI-related problems, compared to 144
(1.7%) of the other group; 3 (0.3%) of the hospitalized
Arthrotec patients died during the hospitalization com-
pared to 15 (0.2%) of the other group; 292 (25.3%) Ar-
throtec patients used GPAs compared to 2,117 (25.0%)
of the other group; 131 (11.4%) Arthrotec patients had
GI diagnostic tests compared to 808 (9.5%) of the other
group. None of these outcome differences was statisti-
cally significant. The cost of the GI-related events was
$172/patient-year in the Arthrotec group compared to
$103/patient-year in the other group. 
CONCLUSIONS: Our data showed no significant differ-
ence in GI-related events attributable to Arthrotec compared
to other NSAIDs. Moreover, the cost of managing these
events tends to be higher in the Arthrotec group.
